Overview

Effects of Sulforaphane on Cognitive Function in Patients With Frontal Brain Damage

Status:
Not yet recruiting
Trial end date:
2021-12-31
Target enrollment:
0
Participant gender:
All
Summary
High rates of patients with frontal brain damage show serious cognitive functional deficits, which negatively impact their quality of life and are linked with poor clinical outcomes. Sulforaphane has shown significant antioxidant and cellular protective effects in animal models associated with oxidative stress, such as focal cerebral ischemia, brain inflammation, and intracranial hemorrhage. Preclinical research has shown that sulforaphane can significantly improve spatial localization and working memory impairment after brain damage. The primary aim of this clinical trial is to assess the efficacy of sulforaphane for improving cognitive function in patients with frontal brain damage.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Xiangya Hospital of Central South University
Treatments:
Sulforafan
Sulforaphane
Criteria
Inclusion Criteria:

- 18-65 years old

- Focal lesions were confined to the frontal brain, which is verified by CT or MRI

- Clinical diagnosis of Cognitive deficits using the Chinese version of the Montreal
Cognitive Assessment (MoCA-C) with scores < 26 will be assessed as having cognitive
deficits (<25 for patients educated <12 years)

- be adherent to the continued sulforaphane treatment medication

Exclusion Criteria:

- Previous history of cognitive impairment

- Brain MRI indicating damage was not restricted to the frontal lobe.

- Inability to cooperate with cognitive testing for disturbance of consciousness or
mental disorder

- Pregnancy or maternal lactation

- Life expectancy < 3 months

- CO poisoning, autoimmune encephalitis, intracranial infection, or other types of
diffuse intracranial disease.

- plan to receive radiotherapy during the trial period

- Laboratory examination showing liver and kidney insufficiency or other severe
complications; the presence of diseases which may interfere with the results of the
evaluation

- Involvement in other trials 1 month prior to the start of the trial or during the
trial period